Gadopiclenol in Contrast Enhanced MRI of the Prostate
Status:
SUSPENDED
Trial end date:
2028-02-01
Target enrollment:
Participant gender:
Summary
The fundamental aim of this study is to show that the novel contrast agent Gadopiclenol (Elucirem), with its high relaxivity, facilitates increased contrast enhancement and improved differentiation of clinically significant prostate cancer on Prostate MRI, as categorized by the PI-RADS v2 classification categories.